Prostatype Genomics AB (PROGEN) - Total Liabilities

Latest as of June 2025: Skr7.36 Million SEK ≈ $791.62K USD

Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has total liabilities worth Skr7.36 Million SEK (≈ $791.62K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Prostatype Genomics AB to assess how effectively this company generates cash.

Prostatype Genomics AB - Total Liabilities Trend (2015–2024)

This chart illustrates how Prostatype Genomics AB's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Prostatype Genomics AB to evaluate the company's liquid asset resilience ratio.

Prostatype Genomics AB Competitors by Total Liabilities

The table below lists competitors of Prostatype Genomics AB ranked by their total liabilities.

Company	Country	Total Liabilities
Chiangmai Rimdoi Public Company Limited BK:CRD	Thailand	฿530.03 Million
Pittler Maschinenfabrik AG F:PIT	Germany	€9.15 Million
Strategem Capital Corp V:SGE	Canada	CA$54.00K
Cipta Selera Murni Pt JK:CSMI	Indonesia	Rp45.48 Billion
Global Sukses Solusi Tbk PT JK:RUNS	Indonesia	Rp22.59 Billion
Kokoh Inti Arebama Tbk JK:KOIN	Indonesia	Rp964.70 Billion
Golden Sky Minerals Corp V:AUEN	Canada	CA$529.22K
Sawang Export Public Company Limited BK:SAWANG	Thailand	฿29.78 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Prostatype Genomics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Prostatype Genomics AB.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.20	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.17	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Prostatype Genomics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Prostatype Genomics AB (2015–2024)

The table below shows the annual total liabilities of Prostatype Genomics AB from 2015 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr8.50 Million ≈ $914.84K	-65.37%
2023-12-31	Skr24.55 Million ≈ $2.64 Million	+411.52%
2022-12-31	Skr4.80 Million ≈ $516.45K	+11.68%
2021-12-31	Skr4.30 Million ≈ $462.42K	-20.02%
2020-12-31	Skr5.37 Million ≈ $578.15K	-40.49%
2018-12-31	Skr9.03 Million ≈ $971.49K	-33.07%
2017-12-31	Skr13.49 Million ≈ $1.45 Million	+181.80%
2016-12-31	Skr4.79 Million ≈ $515.11K	-12.42%
2015-12-31	Skr5.47 Million ≈ $588.18K	--

About Prostatype Genomics AB

ST:PROGEN Sweden Diagnostics & Research

Market Cap

$4.83 Million

Skr44.87 Million SEK

Market Cap Rank

#28433 Global

#645 in Sweden

Share Price

Skr0.76

Change (1 day)

-5.72%

52-Week Range

Skr0.30 - Skr2.50

All Time High

Skr1803.71